12 hours Ago By Defense World Staff
Miramar Capital LLC raised its position in shares of AbbVie Inc. ( NYSE:ABBV – Free Report ) by 0.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission.
The firm owned 102,841 shares of the company’s stock after acquiring an additional 764 shares during the period. AbbVie makes up 4.4% of Miramar Capital LLC’s portfolio, making the stock its 4th biggest position.
Miramar Capital LLC’s holdings in AbbVie were worth $17,639,000 at the end of the most recent quarter. A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc.
boosted its position in shares of AbbVie by 6.2% in the first quarter. Vanguard Group Inc.
now owns 170,376,746 shares of the company’s stock worth $31,025,605,000 after buying an additional 9,978,415 shares during the period. Capital International Investors boosted its position in shares of AbbVie by 6.9% in the first quarter.
Capital International Investors now owns 48,098,784 shares of the company’s stock worth $8,758,789,000 after buying an additional 3,110,601 shares during the period. Capital Research Global Investors lifted its stake in shares of AbbVie by 3.3% in the first quarter.
Capital Research Global Investors now owns 31,295,150 shares of the company’s stock worth $5,698,847,000 after acquiring an additional 992,496 shares in the last quarter. Janus Henderson Group PLC lifted its stake in shares of AbbVie by 12.8% in the first quarter.
Janus Henderson Group PLC now owns 10,898,246 shares of the company’s stock worth $1,984,490,000 after acquiring an additional 1,240,434 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of AbbVie by 13.
7% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,744,190 shares of the company’s stock worth $1,956,518,000 after acquiring an additional 1,291,201 shares in the last quarter.
Hedge funds and other institutional investors own 70.23% of the company’s stock. Insider Buying and Selling In other AbbVie news, Chairman Richard A.
Gonzalez sold 66,500 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $186.52, for a total transaction of $12,403,580.
00. Following the completion of the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48.
The sale was disclosed in a filing with the SEC, which is accessible through the SEC website . In other AbbVie news, Chairman Richard A. Gonzalez sold 282,845 shares of the stock in a transaction on Wednesday, July 17th.
The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.00.
Following the completion of the transaction, the chairman now directly owns 513,099 shares of the company’s stock, valued at approximately $89,792,325. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website . Also, Chairman Richard A.
Gonzalez sold 66,500 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.
00. Following the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at $83,299,645.48.
The disclosure for this sale can be found here . Corporate insiders own 0.25% of the company’s stock.
Wall Street Analyst Weigh In Check Out Our Latest Report on AbbVie AbbVie Stock Performance Shares of ABBV stock opened at $192.89 on Thursday. AbbVie Inc.
has a 12-month low of $135.85 and a 12-month high of $199.95.
The firm has a market capitalization of $340.62 billion, a price-to-earnings ratio of 57.24, a price-to-earnings-growth ratio of 2.
66 and a beta of 0.64. The business has a 50 day simple moving average of $188.
41 and a 200 day simple moving average of $175.58. The company has a debt-to-equity ratio of 8.
51, a current ratio of 0.81 and a quick ratio of 0.71.
AbbVie ( NYSE:ABBV – Get Free Report ) last issued its quarterly earnings data on Thursday, July 25th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.
57 by $0.08. AbbVie had a return on equity of 203.
66% and a net margin of 9.71%. The business had revenue of $14.
46 billion during the quarter, compared to analyst estimates of $14.02 billion. During the same period in the prior year, the company posted $2.
91 EPS. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year.
On average, equities research analysts anticipate that AbbVie Inc. will post 10.86 EPS for the current year.
AbbVie Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be issued a $1.55 dividend.
This represents a $6.20 dividend on an annualized basis and a yield of 3.21%.
The ex-dividend date is Tuesday, October 15th. AbbVie’s dividend payout ratio (DPR) is 183.98%.
AbbVie Profile ( Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. See Also Five stocks we like better than AbbVie How to Know Which Cryptocurrency to Buy: A Guide for Investors How Much Can You Make in Stocks in One Month? What is an Earnings Surprise? This Is the Top Large-Cap Stock Insiders Are Buying What Are Trending Stocks? Trending Stocks Explained Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for AbbVie Inc. ( NYSE:ABBV – Free Report ). Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.
com's FREE daily email newsletter ..
